Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Latexin deletion in the bone marrow niche suppresses leukemia via LIFR downregulation and immune activation
Cuiping Zhang, Xia Yao, Pinpin Sui, Liming Hou, Bowen Yan, Larry L. Luchsinger, Gang Huang, Sheng Tong, Youwen Zhang, Bojing Shao, Hong Qian, Hong Zheng, Hui Zhong, Feng-Chun Yang, Ying Liang
Cuiping Zhang, Xia Yao, Pinpin Sui, Liming Hou, Bowen Yan, Larry L. Luchsinger, Gang Huang, Sheng Tong, Youwen Zhang, Bojing Shao, Hong Qian, Hong Zheng, Hui Zhong, Feng-Chun Yang, Ying Liang
View: Text | PDF
Research Article Hematology Oncology

Latexin deletion in the bone marrow niche suppresses leukemia via LIFR downregulation and immune activation

  • Text
  • PDF
Abstract

Acute myeloid leukemia (AML) is the most common adult leukemia diagnosis. Bone marrow (BM) niche significantly influences the initiation and progression of AML. However, our knowledge about the effect of leukemic niche on leukemia stem cells (LSC) and leukemogenesis is limited. In this study, we identified an extrinsic-regulatory function of latexin (Lxn) in leukemogenesis. Using a MLL-AF9–induced AML mouse model in WT and Lxn-KO (Lxn–/–) recipient mice, we found that Lxn deletion in the BM niche enhanced the survival of AML mice by suppressing LSCs and reducing blood blasts. Single-cell RNA-seq of stromal cells and cell communication analysis uncovered downregulation of the leukemia inhibitory factor receptor (LIFR) signaling pathway in the Lxn–/– niche, particularly within mesenchymal stromal cells (MSCs). Mechanistically, reduced LIFR level in Lxn–/– MSCs upregulated Cxcl9 expression, leading to increased recruitment of CD8 T cells and enhanced cytotoxicity against leukemic cells. Combination of Lxn niche deletion and immune checkpoint inhibitor PD-1 further prolonged survival. The findings have important clinical implications, suggesting that Lxn inhibition could improve the efficacy of AML therapies by targeting the leukemia niche and enhancing immune surveillance.

Authors

Cuiping Zhang, Xia Yao, Pinpin Sui, Liming Hou, Bowen Yan, Larry L. Luchsinger, Gang Huang, Sheng Tong, Youwen Zhang, Bojing Shao, Hong Qian, Hong Zheng, Hui Zhong, Feng-Chun Yang, Ying Liang

×

Figure 7

Lxn deletion in the niche enhances anti–PD-1 treatment efficacy of AML.

Options: View larger image (or click on image) Download as PowerPoint
Lxn deletion in the niche enhances anti–PD-1 treatment efficacy of AML.
...
(A) Experimental scheme for anti–PD-1 antibody treatment in MLL-AF9–driven AML mouse model. (B) Percentages of GFP+ leukemic blasts in PB at day 17 (pretreatment) and day 42 (posttreatment) after transplantation. Data are shown as mean ± SD for the indicated number of mice from a single experiment. (C) Weight loss of leukemic mice on day 42 after anti–PD-1 treatment compared with baseline. Data are shown as mean ± SD for the indicated number of mice from a single experiment. (D) Kaplan-Meier survival curve of leukemic mice with or without anti–PD-1 treatment. WT control (Con) group, n = 19; Lxn–/– Con group, n = 20; WT anti–PD-1 group, n = 15; and Lxn–/– anti–PD-1 group, n = 15. Overall differences were analyzed using the log-rank (Mantel-Cox) test, followed by pairwise comparisons with Holm-Šídák correction for multiple testing. Data are shown as mean ± SD for the indicated number of mice from 3 independent experiments. (E) Model of Lxn deletion in the BM niche and its effect on MLL-AF9 AML. Loss of Lxn downregulates LIFR signaling, leading to increased CXCL9 expression. Elevated CXCL9 recruits more cytotoxic CD8+ T cells, enhancing AML cell killing. Comparisons among 3 or more groups were performed using 1-way ANOVA followed by Tukey’s multiple-comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts